Benefits Plans - Prescription Drug Plan: Drug Plan Updates and New Drug Releases - Drug Reviews

Page last updated: Wednesday, 26-May-2010 20:51:32 EDT

August 2006

The following drug considerations were reviewed and determined for formulary inclusion and tier placement by the U-M Pharmaceutical Benefits Advisory Committee in August 2006.

Drug Name Indication PDL Class
Yes/No
Action
Azilect Parkinsons No Tier 3
Sprycel HIV No Tier 2, eff 8-1-06
Prezista HIV No Tier 2, eff 8-1-06
Atripla HIV No Tier 3
Zelapar ODT Parkinsons No Tier 3
Retrovir HIV No Tier 3 eff 8-1-06, generic market entry
MetroLotion Rosacea No Tier 3 eff 8-1-06, generic market entry
Zithromax susp Antibiotic Yes Tier 3 eff 8-1-06, generic market entry
Zaditor OS  allergic conjunctivitis No Tier 3 eff 8-1-06, generic market entry
Zoloft Antidepressant Yes Tier 3 eff 9-1-06, generic market entry
Effexor Antidepressant Yes Tier 3 eff 9-1-06, generic market entry
Plavix Antiplatelet No Tier 3 eff 9-1-06, generic market entry
Rhinocort Aqua  Nasal Steroid Yes Tier 3, eff 10-1-06
Nasacort AQ Nasal Steroid Yes Tier 3, eff 10-1-06
Crestor Cholesterol Yes Tier 3, eff 10-1-06
Advicor Cholesterol Yes Tier 3, eff 10-1-06
Limitations
The University of Michigan in its sole discretion may modify, amend, or terminate the benefits provided with respect to any individual receiving benefits, including active employees, retirees, and their dependents. Although the university has elected to provide these benefits this year, no individual has a vested right to any of the benefits provided. Nothing in these materials gives any individual the right to continued benefits beyond the time the university modifies, amends, or terminates the benefit. Anyone seeking or accepting any of the benefits provided will be deemed to have accepted the terms of the benefits programs and the university's right to modify, amend or terminate them.